Non-Small Cell Lung Cancer
Non-Small Cell Lung Cancer
Advertisement
Jill FeldmanASCO 2025 | July 18, 2025
In the second segment of this interview, Feldman discussed the importance of patient advocacy in clinical trial research.
Jorge Nieva, MDImmunotherapy in NSCLC | July 18, 2025
Jorge Nieva, MD, explains new findings showing how steroids impact survival in patients undergoing ICI therapy.
Stephen V. Liu, MDEGFR+ NSCLC | July 17, 2025
Dr. Liu discusses the implications of the accelerated approval and what the future may hold.
Cecilia BrownASCO 2025 | July 16, 2025
Thorsten Füreder, MD, shares insights from the NSCLC cohort of the phase 2 trial.
Jill FeldmanASCO 2025 | July 15, 2025
Feldman presented on phase 2 patient-reported quality-of-life outcomes from the COCOON trial at the 2025 ASCO Annual Meeting.
Laura LitwinNon-Small Cell Lung Cancer | July 10, 2025
The phase 3 study compared the efficacy data of benmelstobart plus anlotinib with that of pembrolizumab monotherapy.
Ken Culver, MDASCO 2025 | July 10, 2025
Dr. Culver discusses the organization's work at ASCO and the importance of having a patient advocacy presence at the meeting.
Laura LitwinEGFR+ NSCLC | July 10, 2025
The results of the interim analysis comparing safety and efficacy were presented at the 2025 ASCO Annual Meeting.
Xiuning Le, MD, PhDNon-Small Cell Lung Cancer | July 7, 2025
Xiuning Le, MD, PhD, discusses the phase 3 trial, which follows the SOHO-01 trial of the oral TKI.
Lung Cancers Today EditorsNon-Small Cell Lung Cancer | July 7, 2025
Researchers compared sacituzumab tirumotecan, a TROP2-directed antibody drug conjugate, with platinum-based chemotherapy.
Laura LitwinEGFR+ NSCLC | July 3, 2025
The approval is for adults who have experienced disease progression on or after platinum-based chemotherapy.
Lung Cancers Today EditorsConference Coverage | July 3, 2025
Other analyses suggest that lack of ctDNA clearance with neoadjuvant therapy or with MRD postsurgery leads to worse outcomes.
Lung Cancers Today EditorsASCO 2025 | July 2, 2025
The study investigated HER3-DXd in patients with advanced EGFRm NSCLC after progression during treatment with an EGFR TKI.
Lung Cancers Today EditorsNon-Small Cell Lung Cancer | July 1, 2025
Learn more about outcomes from the first minimal residual disease analysis of the DART trial.
Alexi Archambault, PhD, MPHASCO 2025 | June 30, 2025
Dr. Archambault discusses the safety and effectiveness of cemiplimab plus chemotherapy for first-line treatment of aNSCLC.
Paul Conkling, MDASCO 2025 | June 27, 2025
Dr. Conkling shared his research insights on PD-L1 testing practices for mNSCLC within US community oncology settings.
Sanjay Juneja, MDNon-Small Cell Lung Cancer | June 25, 2025
Sanjay Juneja, MD, with experts Dr. Liu, Dr. Das, and Dr. Singhi, answered major questions about oncology referrals in NSCLC.
Sanjay Juneja, MDNon-Small Cell Lung Cancer | June 25, 2025
Sanjay Juneja, MD, with experts Dr. Liu, Dr. Das, and Dr. Singhi, answered major questions about recent NSCLC innovations.
Sanjay Juneja, MDNon-Small Cell Lung Cancer | June 25, 2025
Sanjay Juneja, MD, directed a discussion with Dr. Liu, Dr. Das, and Dr. Singhi on key updates in the field of NSCLC.
Jessica Bauman, MDASCO 2025 | July 14, 2025
Jessica Bauman, MD, discusses a new analysis of the REACH PC study that she presented at ASCO 2025.
Advertisement